Vildagliptin: optimal control in type 2 diabetes mellitus treatment
Incretin hormones are important for normal pancreatic islet function and glucose homeostasis. Sensitivity to glucose of the α- and β-cells of the pancreas is diminished in type 2 diabetes mellitus (T2DM), leading to impaired insulin secretion, insulin resistance due to elevated glucagon levels in hy...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | article |
| Lenguaje: | EN RU |
| Publicado: |
Endocrinology Research Centre
2015
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/2ee27128d50d4f50b47926bff32edca5 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:2ee27128d50d4f50b47926bff32edca5 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:2ee27128d50d4f50b47926bff32edca52021-11-14T09:00:20ZVildagliptin: optimal control in type 2 diabetes mellitus treatment2072-03512072-037810.14341/DM7599https://doaj.org/article/2ee27128d50d4f50b47926bff32edca52015-12-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/7599https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Incretin hormones are important for normal pancreatic islet function and glucose homeostasis. Sensitivity to glucose of the α- and β-cells of the pancreas is diminished in type 2 diabetes mellitus (T2DM), leading to impaired insulin secretion, insulin resistance due to elevated glucagon levels in hyperglycaemia and impaired glucagon counterregulation in hypoglycaemia. In addition, T2DM is associated with increased lipotoxicity-induced insulin resistance. This article is a comprehensive review of the safety and efficacy of vildagliptin in patients with T2DM and evaluates the extra-pancreatic effects of incretin-based therapies. Clinical evidence has proven that vildagliptin effectively decreases HbA1c with a low risk of hypoglycaemia and is weight neutral. Vildagliptin also suppresses postprandial triglyceride (TG)-rich lipoprotein levels after ingestion of fat-rich meals and reduces fasting lipolysis, suggesting inhibition of fat absorption and reduced TG stores in non-fat tissues.Alexander Sergeevich AmetovEndocrinology Research Centrearticlediabetes mellitusglucagon-like peptide-1glucose-dependent insulinotropic polypeptideinsulin resistancevildagliptinefficacysafetyNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 18, Iss 4, Pp 125-129 (2015) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN RU |
| topic |
diabetes mellitus glucagon-like peptide-1 glucose-dependent insulinotropic polypeptide insulin resistance vildagliptin efficacy safety Nutritional diseases. Deficiency diseases RC620-627 |
| spellingShingle |
diabetes mellitus glucagon-like peptide-1 glucose-dependent insulinotropic polypeptide insulin resistance vildagliptin efficacy safety Nutritional diseases. Deficiency diseases RC620-627 Alexander Sergeevich Ametov Vildagliptin: optimal control in type 2 diabetes mellitus treatment |
| description |
Incretin hormones are important for normal pancreatic islet function and glucose homeostasis. Sensitivity to glucose of the α- and β-cells of the pancreas is diminished in type 2 diabetes mellitus (T2DM), leading to impaired insulin secretion, insulin resistance due to elevated glucagon levels in hyperglycaemia and impaired glucagon counterregulation in hypoglycaemia. In addition, T2DM is associated with increased lipotoxicity-induced insulin resistance. This article is a comprehensive review of the safety and efficacy of vildagliptin in patients with T2DM and evaluates the extra-pancreatic effects of incretin-based therapies. Clinical evidence has proven that vildagliptin effectively decreases HbA1c with a low risk of hypoglycaemia and is weight neutral. Vildagliptin also suppresses postprandial triglyceride (TG)-rich lipoprotein levels after ingestion of fat-rich meals and reduces fasting lipolysis, suggesting inhibition of fat absorption and reduced TG stores in non-fat tissues. |
| format |
article |
| author |
Alexander Sergeevich Ametov |
| author_facet |
Alexander Sergeevich Ametov |
| author_sort |
Alexander Sergeevich Ametov |
| title |
Vildagliptin: optimal control in type 2 diabetes mellitus treatment |
| title_short |
Vildagliptin: optimal control in type 2 diabetes mellitus treatment |
| title_full |
Vildagliptin: optimal control in type 2 diabetes mellitus treatment |
| title_fullStr |
Vildagliptin: optimal control in type 2 diabetes mellitus treatment |
| title_full_unstemmed |
Vildagliptin: optimal control in type 2 diabetes mellitus treatment |
| title_sort |
vildagliptin: optimal control in type 2 diabetes mellitus treatment |
| publisher |
Endocrinology Research Centre |
| publishDate |
2015 |
| url |
https://doaj.org/article/2ee27128d50d4f50b47926bff32edca5 |
| work_keys_str_mv |
AT alexandersergeevichametov vildagliptinoptimalcontrolintype2diabetesmellitustreatment |
| _version_ |
1718429515157340160 |